Tissue engineering heart valves: Valve leaflet replacement study in a lamb model

Shinoka, Toshiharu; Breuer, Christopher K.; Tanel, Ronn E.; Zünd, Gregor; Miura, Takuya; Peter, X.; Langer, Robert; Vacanti, Joseph P.; Mayer, John E.

doi:10.1016/0003-4975(95)00733-4

Cited by 452 publications

(293 citation statements)

References 9 publications

Supporting

Mentioning

285

Contrasting

Unclassified

Order By: Relevance

“…Previously, we reported the advantages of tissueengineered vascular autografts (TEVAs) in dog, 2 lamb, [3][4][5][6] and human clinical applications 7 using biodegradable scaffolds. The key benefit from using such scaffolds is that they degrade in vivo, thereby avoiding the long-term presence of foreign materials 8 as the seeded cells proliferate to form new tissue.…”

mentioning

confidence: 99%

First Evidence That Bone Marrow Cells Contribute to the Construction of Tissue-Engineered Vascular Autografts In Vivo

et al. 2003

View full text Add to dashboard Cite

Background-Materials commonly used to repair complex cardiac defects lack growth potential and have other unwanted side effects. We designed and tested a bone marrow cell (BMC)-seeded biodegradable scaffold that avoids these problems. Methods and Results-To demonstrate the contribution of the BMCs to histogenesis, we labeled them with green fluorescence, seeded them onto scaffolds, and implanted them in the inferior vena cava of dogs. The implanted grafts were analyzed immunohistochemically at 3 hours and subsequently at 2, 4, and 8 weeks after implantation using antibodies against endothelial cell lineage markers, endothelium, and smooth muscle cells. There was no stenosis or obstruction caused by the tissue-engineered vascular autografts (TEVAs) implanted into the dogs. Immunohistochemically, the seeded BMCs expressing endothelial cell lineage markers, such as CD34, CD31, Flk-1, and Tie-2, adhered to the scaffold. This was followed by proliferation and differentiation, resulting in expression of endothelial cells markers, such as CD146, factor VIII, and CD31, and smooth muscle cell markers, such as ␣-smooth muscle cell actin, SMemb, SM1, and SM2. Vascular endothelial growth factor and angiopoietin-1 were also produced by cells in TEVAs. Conclusions-These results provide direct evidence that the use of BMCs enables the establishment of TEVAs. These TEVAs are useful for cardiovascular surgery in humans and especially in children, who require biocompatible materials with growth potential, which might reduce the instance of complications caused by incompatible materials and lead to a reduced likelihood of further surgery.

show abstract

mentioning

confidence: 99%

First Evidence That Bone Marrow Cells Contribute to the Construction of Tissue-Engineered Vascular Autografts In Vivo

et al. 2003

View full text Add to dashboard Cite

show abstract

“…Out of these vessels, two cell types can be isolated: Endothelial cells (ECs) with antithrombogenic properties and myofibroblasts capable of ECM development [16][17][18]. After preliminary studies, mainly in sheep [16][17][18][19][20][21], the potential of human vascular-derived cells was evaluated by seeding on biodegradable scaffolds and revealed excellent tissue formation [15,22,23]. A promising alternative cell source for regenerative medicine is bone marrow-derived stem cells (BMSCs) [3,24,25].…”

Section: Strategies In Tissue Engineering: In Vivo or Ex Vivo?mentioning

confidence: 99%

“…Differentiated ECs have been isolated from vascular sources exhibiting promising results in heart valve tissue engineering [16,19,20,22]. Furthermore, endothelial Another interesting cell source is the umbilical cord, containing several cell types that can be used for heart valve tissue engineering: (1) umbilical cord vein-derived and artery-derived cells, (2) Wharton's Jelly-derived MSCs, and (3) umbilical cord blood-derived EPCs.…”

Section: Strategies In Tissue Engineering: In Vivo or Ex Vivo?mentioning

confidence: 99%

Tissue engineering on matrix: future of autologous tissue replacement

et al. 2011

View full text Add to dashboard Cite

show abstract

“…Results of implantation of a tissue engineered valve leaflet in a lamb model have been reported (Shinoka et al, 1995(Shinoka et al, , 1996Shinoka and Mayer, 1997). In these studies, ovine endothelial cells and myofibroblasts, the cell types normally found in the valve structure, were seeded onto highly porous polyglycolic acid materials under static conditions.…”

Section: Tissue Engineered Heart Valvesmentioning

confidence: 99%

Tissue engineering in the cardiovascular system: Progress toward a tissue engineered heart

Mann

West

2001

Anat. Rec.

View full text Add to dashboard Cite

Achieving the lofty goal of developing a tissue engineered heart will likely rely on progress in engineering the various components: blood vessels, heart valves, and cardiac muscle. Advances in tissue engineered vascular grafts have shown the most progress to date. Research in tissue-engineered vascular grafts has focused on improving scaffold design, including mechanical properties and bioactivity; genetically engineering cells to improve graft performance; and optimizing tissue formation through in vitro mechanical conditioning. Some of these same approaches have been used in developing tissue engineering heart valves and cardiac muscle as well. Continued advances in scaffold technology and a greater understanding of vascular cell biology along with collaboration among engineers, scientists, and physicians will lead to further progress in the field of cardiovascular tissue engineering and ultimately the development of a tissue-engineered heart.

show abstract

Tissue engineering heart valves: Valve leaflet replacement study in a lamb model

Cited by 452 publications

References 9 publications

First Evidence That Bone Marrow Cells Contribute to the Construction of Tissue-Engineered Vascular Autografts In Vivo

First Evidence That Bone Marrow Cells Contribute to the Construction of Tissue-Engineered Vascular Autografts In Vivo

Tissue engineering on matrix: future of autologous tissue replacement

Tissue engineering in the cardiovascular system: Progress toward a tissue engineered heart

Contact Info

Product

Resources

About